Fundraising Fox

Alexandra (Sandra) Glucksmann

Investor

Advisory Partner at Adjuvant Capital

Boston

About

Sandra Glucksmann joined Adjuvant Capital as an Advisory Partner and Investment Committee member in 2023, and is CEO of Sensorium Therapeutics. She has over 30 years in biotech, serving as founding CEO and President of Cedilla Therapeutics and founding COO of Editas Medicine. She holds a Ph.D. in molecular genetics and cell biology from the University of Chicago.

Invests in

Biotech

Experience

  1. Rouge TherapeuticsBoard Executive Chaircurrent2025 β€” presentNetherlands
  2. Tufts University School of MedicineTUSM Board of Advisorscurrent2024 β€” presentBoston, Massachusetts, United States
  3. REGENXBIO Inc.Independent Board Membercurrent2018 β€” presentRockville, MD
  4. Adjuvant CapitalAdvisory Partnercurrent2023 β€” presentUnited States
  5. Edity TherapeuticsBoard Membercurrent2022 β€” presentRehovot, Israel
  6. Scenic BiotechSenior Advisorcurrent2024 β€” presentAmsterdam, North Holland, Netherlands
  7. Scenic BiotechIndependent Board Member2017 β€” 2024The Randstad, Netherlands
  8. Sensorium TherapeuticsBoard Member and Senior Advisor2025
  9. Sensorium TherapeuticsPresident & CEO2023 β€” 2025Boston, Massachusetts, United States
  10. Cedilla TherapeuticsPresident and CEO2018 β€” 2022Cambrdige, MA
  11. WEST - Women in the Enterprise of Science and TechnologyMember Board of Directors2017 β€” 2020Cambridge, MA
  12. WEST - Women in the Enterprise of Science and TechnologyChair Board of Directors2006 β€” 2017Cambridge, MA
  13. Third Rock VenturesEntrepreneur In Residence2017 β€” 2018
  14. Editas MedicineChief Operating Officer2013 β€” 2017
  15. TaconicIndependent Board Member2006 β€” 2015
  16. Cerulean PharmaSenior VP Research and Development2006 β€” 2013Cambridge, MA
  17. Cerulean PharmaSenior VP Research & Business Operations2006 β€” 2011
  18. Millennium PharmaceuticalsFrom Scientist to VP1993 β€” 2006

Education

  1. Massachusetts Institute of TechnologyPost-doctoral fellow, Molecular Biology1990 β€” 1993
  2. University of ChicagoPhD Molecular Genetics and Cell Biology1983 β€” 1989
  3. University of Wisconsin-MadisonBachelor of Science - BS

Skills & more

Research1Biotechnology32Lifesciences8Commercialization5Technology Transfer5Medical Devices3Molecular Biology7Biochemistry5Start-ups5Cross-functional Team Leadership4Oncology7Biopharmaceuticals16
+3 moreDrug DiscoveryProduct DevelopmentPharmaceutical Industry

Languages Spanish

From Alexandra's professional profile.

Same school

Shared employers

Investments

Board seats

REGENXBIOScenic Biotech

Per the firm's website.

Colleagues at Adjuvant Capital